Emerging structural heart procedures creating new transseptal access demand — the growing pipeline of transcatheter interventions for tricuspid valve disease, mitral valve replacement, left ventricular assist device implantation approaches, and novel cardiac interventions requiring transseptal access — represents the future market expansion opportunity for transseptal access technology, with the Transseptal Access System Market reflecting new indication development as a market growth driver.

Transcatheter tricuspid valve interventions — the rapidly developing commercial market for transcatheter tricuspid edge-to-edge repair (TEER) with TriClip (Abbott) and PASCAL tricuspid (Edwards), transcatheter tricuspid valve replacement (TTVR) programs — represents emerging transseptal volume. While tricuspid access for right-sided interventions primarily uses direct right heart access, transseptal techniques are needed for some tricuspid approaches and for combined mitral-tricuspid interventions.

Transcatheter mitral valve replacement — the ambitious TMVR programs (Tendyne, Intrepid, Tiara, Cardiovalve, and others) aiming to replace the mitral valve entirely via transcatheter approaches — represent high-complexity structural heart procedures requiring transseptal access as the delivery route for most TMVR devices. The technical demands of delivering large mitral valve prostheses through transseptal access creating the requirement for even larger bore transseptal systems than current MitraClip procedures.

Electrophysiology expansion — the growing adoption of pulsed field ablation (PFA) for AF ablation (Farapulse/Boston Scientific, Affera/Medtronic, other platforms) requiring transseptal access — creates the most rapidly growing new technology driver for transseptal volume. PFA's advantages (no esophageal injury, pulmonary vein stenosis, or phrenic nerve injury from cardiac muscle-specific electroporation) driving adoption will increase total AF ablation volumes and thereby transseptal procedure volumes.

Do you think TMVR programs will eventually achieve sufficient commercial maturity to compete with MitraClip repair for the transcatheter mitral valve market, and how would successful TMVR commercialization affect the transseptal access market?

FAQ

What is pulsed field ablation and how does it affect transseptal access? Pulsed field ablation (PFA) for AF: Mechanism: electroporation — ultra-short, high-voltage electrical pulses creating irreversible pores in cardiomyocyte cell membranes causing cell death; cardiac muscle selectivity from cardiomyocyte-specific sensitivity to electroporation; spares esophagus, phrenic nerve, pulmonary vein from different tissue sensitivity thresholds; Advantages over thermal ablation: no esophageal thermal injury (one of most feared AF ablation complications from RF posterior wall ablation — ≤1% atrial-esophageal fistula risk with RF); reduced phrenic nerve injury; no pulmonary vein stenosis risk; faster procedure from single-shot delivery; early systems: Farapulse PFA catheter (Boston Scientific) — basket catheter with pentaspline design; single-shot pulmonary vein isolation; FDA approved 2023; rapidly gaining adoption; Affera Sphere-9 (Medtronic) — multielectrode catheter; grid pattern; approved 2024; VARIPULSE (Biosense Webster/J&J) — variable loop catheter; multiple competitors in development; Transseptal access implications: PFA procedures require same transseptal access as RF ablation; large deflectable sheath for Farapulse; standard eight-point-five French sheath; ICE guidance standard; faster procedure time may increase annual volume per operator; overall AF ablation volume expected to grow with PFA adoption from improved safety; direct impact on transseptal access volume.

What TMVR programs are in clinical development? Transcatheter mitral valve replacement pipeline: Tendyne (Abbott) — apical approach; mitral ring anchoring; pivotal Tendyne Global Feasibility Trial positive; high-risk surgical patients; CE mark (Europe) and regulatory pathway; Intrepid (Medtronic) — transseptal or transapical approach; outer anchoring dock and inner valve; APOLLO trial ongoing Phase III; Tiara (Neovasc) — D-shaped design matching native mitral anatomy; TIARA-II trial; limited adoption; Cardiovalve (Valfix/Cardiovalve) — subannular anchoring; transseptal; clinical development; GATE (4C Medical) — percutaneous leaflet clipping plus valve; Sapien 3 valve-in-mitral annular calcification — off-label use growing; TMVR challenges: large device size (mitral annulus much larger than aortic); complex three-dimensional anatomy; LVOT obstruction risk from anterior leaflet displacement; complex transseptal requirements from device size; Transseptal access for TMVR: requires very large bore transseptal sheaths (twenty-four to thirty-two French); new generation large-bore transseptal systems under development; precise crossing location from device-specific geometry requirements; current market: TMVR in early commercial or late clinical stage; not significant commercial transseptal volume yet; five-year horizon for substantial TMVR-driven transseptal market contribution.

#TransseptalAccess #PulsedFieldAblation #Farapulse #TMVR #EmergingStructuralHeart #TransseptalFuture